---
provider: falcon
model: Edison Scientific Literature
cached: false
start_time: '2025-12-26T10:33:14.392442'
end_time: '2025-12-26T10:40:17.204187'
duration_seconds: 422.81
template_file: templates/gene_research_go_focused.md
template_variables:
  organism: human
  gene_id: CAMK2A
  gene_symbol: CAMK2A
  uniprot_accession: Q9UQM7
  protein_description: 'RecName: Full=Calcium/calmodulin-dependent protein kinase
    type II subunit alpha; Short=CaM kinase II subunit alpha; Short=CaMK-II subunit
    alpha; EC=2.7.11.17 {ECO:0000269|PubMed:23805378};'
  gene_info: Name=CAMK2A; Synonyms=CAMKA, KIAA0968;
  organism_full: Homo sapiens (Human).
  protein_family: Belongs to the protein kinase superfamily. CAMK Ser/Thr
  protein_domains: Ca/CaM-dep_prot_kinase-assoc. (IPR013543); Kinase-like_dom_sf.
    (IPR011009); NTF2-like_dom_sf. (IPR032710); Prot_kinase_dom. (IPR000719); Protein_kinase_ATP_BS.
    (IPR017441)
provider_config:
  timeout: 600
  max_retries: 3
  parameters:
    allowed_domains: []
    temperature: 0.1
citation_count: 17
---

## Question

# Gene Research for Functional Annotation

## ⚠️ CRITICAL: Gene/Protein Identification Context

**BEFORE YOU BEGIN RESEARCH:** You MUST verify you are researching the CORRECT gene/protein. Gene symbols can be ambiguous, especially for less well-characterized genes from non-model organisms.

### Target Gene/Protein Identity (from UniProt):
- **UniProt Accession:** Q9UQM7
- **Protein Description:** RecName: Full=Calcium/calmodulin-dependent protein kinase type II subunit alpha; Short=CaM kinase II subunit alpha; Short=CaMK-II subunit alpha; EC=2.7.11.17 {ECO:0000269|PubMed:23805378};
- **Gene Information:** Name=CAMK2A; Synonyms=CAMKA, KIAA0968;
- **Organism (full):** Homo sapiens (Human).
- **Protein Family:** Belongs to the protein kinase superfamily. CAMK Ser/Thr
- **Key Domains:** Ca/CaM-dep_prot_kinase-assoc. (IPR013543); Kinase-like_dom_sf. (IPR011009); NTF2-like_dom_sf. (IPR032710); Prot_kinase_dom. (IPR000719); Protein_kinase_ATP_BS. (IPR017441)

### MANDATORY VERIFICATION STEPS:

1. **Check if the gene symbol "CAMK2A" matches the protein description above**
2. **Verify the organism is correct:** Homo sapiens (Human).
3. **Check if protein family/domains align with what you find in literature**
4. **If you find literature for a DIFFERENT gene with the same or similar symbol, STOP**

### If Gene Symbol is Ambiguous or You Cannot Find Relevant Literature:

**DO NOT PROCEED WITH RESEARCH ON A DIFFERENT GENE.** Instead:
- State clearly: "The gene symbol 'CAMK2A' is ambiguous or literature is limited for this specific protein"
- Explain what you found (e.g., "Found extensive literature on a different gene with the same symbol in a different organism")
- Describe the protein based ONLY on the UniProt information provided above
- Suggest that the protein function can be inferred from domain/family information

### Research Target:

Please provide a comprehensive research report on the gene **CAMK2A** (gene ID: CAMK2A, UniProt: Q9UQM7) in human.

The research report should be a detailed narrative explaining the function, biological processes, and localization of the gene product. Citations should be given for all claims.

You should prioritize authoritative reviews and primary scientific literature when conducting research. You can supplement
this with annotations you find in gene/protein databases, but these can be outdated or inaccurate.

We are specifically interested in the primary function of the gene - for enzymes, what reaction is catalyzed, and what is the substrate specificity? For transporters, what is the substrate? For structural proteins or adapters, what is the broader structural role? For signaling molecules, what is the role in the pathway.

We are interested in where in or outside the cell the gene product carries out its function.

We are also interested in the signaling or biochemical pathways in which the gene functions. We are less interested in broad pleiotropic effects, except where these elucidate the precise role.

Include evidence where possible. We are interested in both experimental evidence as well as inference from structure, evolution, or bioinformatic analysis. Precise studies should be prioritized over high-throughput, where available.

## Output

Question: You are an expert researcher providing comprehensive, well-cited information.

Provide detailed information focusing on:
1. Key concepts and definitions with current understanding
2. Recent developments and latest research (prioritize 2023-2024 sources)
3. Current applications and real-world implementations
4. Expert opinions and analysis from authoritative sources
5. Relevant statistics and data from recent studies

Format as a comprehensive research report with proper citations. Include URLs and publication dates where available.
Always prioritize recent, authoritative sources and provide specific citations for all major claims.

# Gene Research for Functional Annotation

## ⚠️ CRITICAL: Gene/Protein Identification Context

**BEFORE YOU BEGIN RESEARCH:** You MUST verify you are researching the CORRECT gene/protein. Gene symbols can be ambiguous, especially for less well-characterized genes from non-model organisms.

### Target Gene/Protein Identity (from UniProt):
- **UniProt Accession:** Q9UQM7
- **Protein Description:** RecName: Full=Calcium/calmodulin-dependent protein kinase type II subunit alpha; Short=CaM kinase II subunit alpha; Short=CaMK-II subunit alpha; EC=2.7.11.17 {ECO:0000269|PubMed:23805378};
- **Gene Information:** Name=CAMK2A; Synonyms=CAMKA, KIAA0968;
- **Organism (full):** Homo sapiens (Human).
- **Protein Family:** Belongs to the protein kinase superfamily. CAMK Ser/Thr
- **Key Domains:** Ca/CaM-dep_prot_kinase-assoc. (IPR013543); Kinase-like_dom_sf. (IPR011009); NTF2-like_dom_sf. (IPR032710); Prot_kinase_dom. (IPR000719); Protein_kinase_ATP_BS. (IPR017441)

### MANDATORY VERIFICATION STEPS:

1. **Check if the gene symbol "CAMK2A" matches the protein description above**
2. **Verify the organism is correct:** Homo sapiens (Human).
3. **Check if protein family/domains align with what you find in literature**
4. **If you find literature for a DIFFERENT gene with the same or similar symbol, STOP**

### If Gene Symbol is Ambiguous or You Cannot Find Relevant Literature:

**DO NOT PROCEED WITH RESEARCH ON A DIFFERENT GENE.** Instead:
- State clearly: "The gene symbol 'CAMK2A' is ambiguous or literature is limited for this specific protein"
- Explain what you found (e.g., "Found extensive literature on a different gene with the same symbol in a different organism")
- Describe the protein based ONLY on the UniProt information provided above
- Suggest that the protein function can be inferred from domain/family information

### Research Target:

Please provide a comprehensive research report on the gene **CAMK2A** (gene ID: CAMK2A, UniProt: Q9UQM7) in human.

The research report should be a detailed narrative explaining the function, biological processes, and localization of the gene product. Citations should be given for all claims.

You should prioritize authoritative reviews and primary scientific literature when conducting research. You can supplement
this with annotations you find in gene/protein databases, but these can be outdated or inaccurate.

We are specifically interested in the primary function of the gene - for enzymes, what reaction is catalyzed, and what is the substrate specificity? For transporters, what is the substrate? For structural proteins or adapters, what is the broader structural role? For signaling molecules, what is the role in the pathway.

We are interested in where in or outside the cell the gene product carries out its function.

We are also interested in the signaling or biochemical pathways in which the gene functions. We are less interested in broad pleiotropic effects, except where these elucidate the precise role.

Include evidence where possible. We are interested in both experimental evidence as well as inference from structure, evolution, or bioinformatic analysis. Precise studies should be prioritized over high-throughput, where available.

Plan and verification
- Identity and organism: CAMK2A encodes the human Ca2+/calmodulin-dependent protein kinase II alpha (CaMKIIα), UniProt Q9UQM7. It is a neuronal serine/threonine protein kinase that assembles into multimeric holoenzymes; biochemical and phosphoproteomic studies explicitly use human CAMK2A annotations and purified CAMK2A kinase domains to define activity and substrates (Rigter et al., bioRxiv, 2024; Chia et al., eLife, 2018) (rigter2024simultaneouslossof pages 5-8, chia2018ahomozygouslossoffunction pages 1-2). The architecture includes an N-terminal kinase domain, a regulatory segment with the CaM-binding/autoinhibitory region, and a C-terminal association (hub) domain that mediates oligomerization (Chia et al., eLife, 2018) (chia2018ahomozygouslossoffunction pages 1-2).

1) Key concepts and definitions
- Enzyme class and catalytic activity: CaMKIIα is a serine/threonine protein kinase (EC 2.7.11.17) with a modest preference for serine over threonine in cellular contexts. Purified CAMK2A catalytic domain supports Michaelis–Menten kinetics in NADH-coupled in vitro kinase assays, and sequence analyses from cortical phosphoproteomics confirm a canonical CaMKII motif with basic residue enrichment at −3 and hydrophobic residues at +1 (Rigter et al., bioRxiv, 2024; methods and motif analysis) (rigter2024simultaneouslossof pages 5-8, rigter2024simultaneouslossof pages 17-19).
- Autoinhibition and activation: At rest, the regulatory segment occludes the active site; Ca2+/calmodulin binding relieves autoinhibition to activate the kinase. This mechanism links Ca2+ entry (e.g., via NMDARs) to CaMKII activation during synaptic plasticity (Chia et al., eLife, 2018; review citations collated in Rigter et al., 2024) (chia2018ahomozygouslossoffunction pages 19-19, rigter2024simultaneouslossof pages 19-21).
- Autophosphorylation sites and effects: Autophosphorylation of Thr286 (CaMKIIα) produces calcium-independent “autonomous” activity following Ca2+/CaM dissociation. In vivo phosphoproteomics of double Camk2a/b loss shows Thr286 (and the homologous Thr287 in CAMK2B) among the most reduced phosphosites, consistent with CAMK2 dependency (Rigter et al., bioRxiv, 2024) (rigter2024simultaneouslossof pages 17-19, rigter2024simultaneouslossof pages 12-15). Phosphorylation of regulatory Thr305/306 (within the CaM-binding segment) is classically inhibitory; however, at baseline in cortical tissue these sites were not readily detected, while methodological work cautions that the commonly used T305A/T306A “AA” mutant creates an unintended gain-of-function by promoting tight α-actinin-2 binding and spine enlargement without stimulation (Curtis et al., bioRxiv, 2025; Rigter et al., 2024) (curtis2025widelyusedcamkii pages 1-5, rigter2024simultaneouslossof pages 12-15).
- Holoenzyme architecture: CaMKII subunits assemble via the association (hub) domain into 12- or 14-subunit rings (polymorphism across isoforms). The human disease variant CAMK2A His477Tyr (association domain) disrupts self-oligomerization and prevents holoenzyme assembly, demonstrating the hub domain’s functional necessity (Chia et al., eLife, 2018). Structural and regulatory literature cited in recent phosphoproteomic studies describe activation-triggered dynamics within the holoenzyme (Rigter et al., 2024) (chia2018ahomozygouslossoffunction pages 1-2, rigter2024simultaneouslossof pages 19-21).
- Localization and targeting: CaMKIIα is abundant in dendritic spines and the postsynaptic density (PSD). After strong synaptic activity, CaMKII rapidly docks to NMDARs via GluN2B, localizing activity to the PSD. Disruption of holoenzyme assembly (H477Y) impairs these synaptic functions (Chia et al., eLife, 2018; overview in Rigter et al., 2024) (chia2018ahomozygouslossoffunction pages 19-19, rigter2024simultaneouslossof pages 19-21).

2) Recent developments and latest research (prioritizing 2023–2024)
- Endogenous substrate discovery in vivo: In an inducible Camk2a/2b double-knockout cortex, phosphopeptide enrichment identified 5,830 phosphopeptides (2,210 proteins). Of these, 208 phosphopeptides (130 proteins) were downregulated >1.5-fold upon CAMK2 loss, revealing endogenous CAMK2-dependent sites under basal conditions. Notably, the strongest downregulated site was SHANK3 Ser1510, validated as a direct CAMK2A target in vitro. Multiple known PSD proteins (e.g., SYNGAP1, DLGAP family) showed decreased phosphorylation, underscoring CAMK2’s central role in postsynaptic organization (Rigter et al., bioRxiv, Nov 17, 2024; DOI: 10.1101/2024.11.17.624016) (rigter2024simultaneouslossof pages 5-8, rigter2024simultaneouslossof pages 12-15).
- Substrate motif and site biases: Sequence analysis of the downregulated sites supported a CaMKII motif with a −3 basic residue, +1 hydrophobic residue, and a +2 acidic residue that modulates catalytic efficiency; the analysis also indicated a modest serine bias among affected sites. CAMK2 autophosphorylation sites showed heterogeneous decreases (e.g., Thr286 and Ser314 down ~80% vs. Ser275/Thr333 down ~50%), suggesting differential regulation across sites and isoforms (Rigter et al., 2024) (rigter2024simultaneouslossof pages 12-15).
- Methodological standards and mutant caveats: Structural/functional work highlights that T305/T306 substitutions can inadvertently rewire CaMKII interactions (e.g., α-actinin-2 binding), potentially confounding interpretations of “inhibitory-site” manipulations (Curtis et al., bioRxiv, Mar 2025; preprint DOI: 10.1101/2025.03.18.643923) (curtis2025widelyusedcamkii pages 1-5).

3) Current applications and real-world implementations
- Small-molecule inhibitor discovery: Translational work identified ruxolitinib as a potent and cardioprotective CaMKII inhibitor with improved reporter assays, highlighting potential repurposing for acute cardiac injury; the cardiology translational literature is summarized in the 2024 evidence compilation (Gaido et al., Sci Transl Med, 2023; DOI: 10.1126/scitranslmed.abq7839). However, CaMKII inhibitors have not yet reached clinical practice broadly, partly due to isoform complexity and physiological roles (Rigter et al., 2024, citing translational reviews; Annual Review of Pharmacol. Toxicol. 2023) (rigter2024simultaneouslossof pages 19-21).
- Tool compound limitations: Methodological syntheses emphasize caveats for widely used tool inhibitors (e.g., KN-93) and the importance of orthogonal validation and proper controls when interpreting CaMKII inhibition in cells (Rigter et al., 2024; methods-focused summaries) (rigter2024simultaneouslossof pages 19-21).

4) Expert opinions and analysis from authoritative sources
- Synaptic plasticity centrality: A consensus across decades of work—compiled in recent mechanistic reviews and genetic studies—is that CaMKIIα is essential for LTP induction and learning/memory. Human genetics provide convergent clinical evidence linking CAMK2A dysfunction to severe neurodevelopmental phenotypes (Chia et al., eLife, 2018; literature synthesis in Rigter et al., 2024) (chia2018ahomozygouslossoffunction pages 19-19, rigter2024simultaneouslossof pages 19-21).
- Structural vs enzymatic roles: Recent analysis indicates that, depending on stimulus strength and context, structural interactions of CaMKII (e.g., with GluN2B or actin/actinin) can suffice for aspects of LTP, while the D135N “kinase-dead” mutant also alters GluN2B engagement, complicating clean separation of catalytic versus structural functions. Consequently, careful experimental design and mutant validation are needed when attributing phenotypes to enzymatic vs scaffolding roles (methodological critiques and mutant behavior synthesized in Curtis et al., 2025-preprint and literature cited therein) (curtis2025widelyusedcamkii pages 1-5).

5) Relevant statistics and data from recent studies
- Proteomic scale and differential phosphorylation: 5,830 phosphopeptides (2,210 proteins) identified in cortex; 208 phosphopeptides (130 proteins) downregulated >1.5× in Camk2a/b double KO at baseline. CaMKII autophosphorylation sites decreased to varying extents (e.g., Thr286/Thr287 down ~80%; some other sites ~50%). SHANK3 S1510 showed the strongest downregulation and was biochemically validated as a direct CAMK2A substrate (Rigter et al., bioRxiv, 2024; DOI: 10.1101/2024.11.17.624016) (rigter2024simultaneouslossof pages 5-8, rigter2024simultaneouslossof pages 12-15).
- Human genetics: The homozygous CAMK2A H477Y variant affects the association domain, abolishes oligomerization and fails to rescue neuronal defects in model systems; affected individuals present growth delay, frequent seizures, and severe intellectual disability (eLife, 2018; DOI: 10.7554/eLife.32451) (chia2018ahomozygouslossoffunction pages 1-2).

Primary function, substrates, and pathways (concise mechanistic narrative)
- Function and reaction: CaMKIIα phosphorylates serine/threonine residues on neuronal substrates upon Ca2+/CaM activation, coupling glutamatergic Ca2+ influx to downstream phosphorylation events that strengthen synapses. Autophosphorylation at Thr286 prolongs activity beyond Ca2+ transients and promotes synaptic retention/localization. In vivo and in vitro evidence supports CaMKII action on key PSD scaffolds and signaling proteins (e.g., SHANK3, SYNGAP1, DLGAP family), consistent with its central role in organizing postsynaptic signaling and plasticity (Rigter et al., 2024) (rigter2024simultaneouslossof pages 5-8, rigter2024simultaneouslossof pages 12-15).
- Substrate specificity: Sequence preferences center on a −3 basic residue, +1 hydrophobic residue (often Leu), with a modulating +2 acidic residue; phosphoproteomics show a serine-skew among downregulated sites, aligning with a serine preference in vivo (Rigter et al., 2024) (rigter2024simultaneouslossof pages 12-15).
- Pathway placement and localization: CaMKIIα accumulates at the PSD after NMDAR-dependent Ca2+ influx, binding GluN2B to localize its activity. Loss of proper holoenzyme assembly (e.g., association-domain mutation) disrupts synaptic localization and function. These molecular events underlie LTP/LTD phenomena that ultimately mediate learning and memory (Chia et al., 2018; synthesis in Rigter et al., 2024) (chia2018ahomozygouslossoffunction pages 19-19, rigter2024simultaneouslossof pages 19-21).

Clinical and translational relevance
- Neurodevelopmental disease: CAMK2A variants (including loss-of-function in the hub domain) cause severe neurodevelopmental phenotypes with seizures and cognitive impairment, providing a human genetic link to CaMKII’s central role in synaptic development and function (Chia et al., eLife, 2018; DOI: 10.7554/eLife.32451) (chia2018ahomozygouslossoffunction pages 1-2).
- Therapeutic targeting: Newer small-molecule efforts (e.g., ruxolitinib hit identification with improved CaMKII activity reporters) and translational reviews suggest opportunities but also emphasize challenges of isoform selectivity and avoiding interference with physiological learning/memory roles (Gaido et al., Sci Transl Med, 2023; Annual Rev. Pharmacol. Toxicol., 2023; summarized in Rigter et al., 2024) (rigter2024simultaneouslossof pages 19-21).

URLs and publication dates (selected, recent and authoritative)
- Rigter PMF et al. Simultaneous loss of CAMK2A and CAMK2B reveals endogenous in vivo substrates. bioRxiv. Posted Nov 17, 2024. DOI: 10.1101/2024.11.17.624016; URL: https://doi.org/10.1101/2024.11.17.624016 (rigter2024simultaneouslossof pages 5-8, rigter2024simultaneouslossof pages 17-19, rigter2024simultaneouslossof pages 12-15).
- Chia PH et al. A homozygous loss-of-function CAMK2A mutation causes growth delay, frequent seizures and severe intellectual disability. eLife. 2018 May; DOI: 10.7554/eLife.32451; URL: https://doi.org/10.7554/eLife.32451 (chia2018ahomozygouslossoffunction pages 1-2, chia2018ahomozygouslossoffunction pages 19-19).
- Curtis AJ et al. Widely used CaMKII regulatory segment mutations cause tight actinin binding and dendritic spine enlargement in unstimulated neurons. bioRxiv. Posted Mar 18, 2025. DOI: 10.1101/2025.03.18.643923; URL: https://doi.org/10.1101/2025.03.18.643923 (methodological caveats; recent) (curtis2025widelyusedcamkii pages 1-5).
- Gaido OER et al. An improved reporter identifies ruxolitinib as a potent and cardioprotective CaMKII inhibitor. Science Translational Medicine. 2023 Jun; DOI: 10.1126/scitranslmed.abq7839; URL: https://doi.org/10.1126/scitranslmed.abq7839 (as summarized in the 2024 evidence set) (rigter2024simultaneouslossof pages 19-21).

Summary of verified alignment to UniProt context
- Symbol and description match: CAMK2A encodes CaMKIIα (human), a Ca2+/CaM-activated Ser/Thr kinase (EC 2.7.11.17) central to neuronal signaling. Domain/family context (protein kinase domain and association/hub domain) and oligomeric holoenzyme assembly are consistently supported by human genetic and biochemical data (Chia et al., 2018; Rigter et al., 2024) (chia2018ahomozygouslossoffunction pages 1-2, rigter2024simultaneouslossof pages 5-8).

Embedded summary artifact
| Topic | Finding / Detail (succinct) | Evidence / Key data (select) | Source (journal, year) | URL / DOI |
|---|---|---|---|---|
| Identity verification | CAMK2A encodes CaMKIIα, human (UniProt Q9UQM7); neuronal isoform | UniProt mapping used in phosphoproteomic/biochemical studies; kinase domain residues annotated (7–274) (see phosphoproteomics) (rigter2024simultaneouslossof pages 5-8, rigter2024simultaneouslossof pages 19-21) | Rigter et al., bioRxiv (2024) | https://doi.org/10.1101/2024.11.17.624016 |
| Enzyme class (EC) | Ser/Thr protein kinase (EC 2.7.11.17) with small serine preference | Purified kinase assays (NADH-coupled; Michaelis–Menten) and substrate motif analysis support Ser/Thr kinase classification (rigter2024simultaneouslossof pages 5-8, rigter2024simultaneouslossof pages 17-19) | Rigter et al., bioRxiv (2024) | https://doi.org/10.1101/2024.11.17.624016 |
| Activation by Ca2+/CaM | Autoinhibited at rest; activated by Ca2+/calmodulin binding which relieves autoinhibition | Classical biochemical/regulatory mechanism linking Ca2+ influx to activation and LTP induction (chia2018ahomozygouslossoffunction pages 19-19, rigter2024simultaneouslossof pages 19-21) | Chia et al., eLife (2018); Rigter et al., bioRxiv (2024) | https://doi.org/10.7554/eLife.32451 ; https://doi.org/10.1101/2024.11.17.624016 |
| Autophosphorylation (Thr286) | T286 autophosphorylation produces Ca2+-independent (autonomous) activity after stimulation | T286 (and CAMK2B T287) detected in phosphoproteome; phosphorylation levels drop in CAMK2A/B KO (rigter2024simultaneouslossof pages 17-19, rigter2024simultaneouslossof pages 12-15) | Rigter et al., bioRxiv (2024) | https://doi.org/10.1101/2024.11.17.624016 |
| Regulatory Thr305/306 | T305/306 are inhibitory regulatory sites; commonly used mutants (T305A/T306A) can have unintended gain-of-function effects | AA (T305A/T306A) mutants promote tight α-actinin binding and spine enlargement; Rigter baseline samples did not detect T305/306 phosphorylation (curtis2025widelyusedcamkii pages 1-5, rigter2024simultaneouslossof pages 12-15) | Curtis et al., bioRxiv (2025); Rigter et al., bioRxiv (2024) | https://doi.org/10.1101/2025.03.18.643923 ; https://doi.org/10.1101/2024.11.17.624016 |
| Substrate examples | Notable neuronal substrates: GluA1 (S831, well-known); SYNGAP1 (multiple sites); SHANK3 (S1510 validated) | Rigter phosphoproteomics: SYNGAP1 and DLGAP family phosphosites downregulated >1.5× in CAMK2A/B KO; SHANK3 S1510 was the strongest downregulated site and validated in vitro (rigter2024simultaneouslossof pages 5-8, rigter2024simultaneouslossof pages 12-15) | Rigter et al., bioRxiv (2024) | https://doi.org/10.1101/2024.11.17.624016 |
| Holoenzyme architecture | Forms 12- or 14-subunit holoenzymes (hub polymorphism); association (hub) domain required for oligomerization; domain-swapped/alternative conformations reported | Cryo-EM and structural literature summarized in reviews and observed functional disruption by association-domain mutation H477Y preventing oligomerization (rigter2024simultaneouslossof pages 19-21, chia2018ahomozygouslossoffunction pages 1-2) | Rigter et al., bioRxiv (2024); Chia et al., eLife (2018) | https://doi.org/10.1101/2024.11.17.624016 ; https://doi.org/10.7554/eLife.32451 |
| Localization / targeting | Enriched at postsynaptic density and dendritic spines; synaptic targeting via binding to GluN2B (NMDAR) | Patient mutation H477Y in association domain disrupts holoenzyme assembly and synaptic localization; literature reports rapid CaMKII docking to NMDAR/GluN2B after stimulation (chia2018ahomozygouslossoffunction pages 19-19, rigter2024simultaneouslossof pages 19-21) | Chia et al., eLife (2018); Rigter et al., bioRxiv (2024) | https://doi.org/10.7554/eLife.32451 ; https://doi.org/10.1101/2024.11.17.624016 |
| Roles in LTP / LTD & learning | Central regulator of LTP induction and memory; both enzymatic phosphorylation and structural (scaffolding) roles contribute | Human/mouse genetic perturbations (α-CaMKII mutants, knockout) produce impaired LTP and learning; recent work debates enzymatic vs structural sufficiency (chia2018ahomozygouslossoffunction pages 19-19, curtis2025widelyusedcamkii pages 1-5) | Chia et al., eLife (2018); Curtis et al., bioRxiv (2025) | https://doi.org/10.7554/eLife.32451 ; https://doi.org/10.1101/2025.03.18.643923 |
| 2023–2024 developments | Key recent findings: age-related nitrosylation changes affecting synaptic CaMKII; GluN2B-bound autonomous CaMKII activity localized for LTP expression; hub polymorphism and methodological standards reviews | Recent reviews and experimental papers summarized these themes and motivated new models for autonomy and hub dynamics (rigter2024simultaneouslossof pages 19-21, curtis2025widelyusedcamkii pages 1-5) | Rigter et al., bioRxiv (2024); Curtis et al., bioRxiv (2025); related literature (2023–2024) | https://doi.org/10.1101/2024.11.17.624016 ; https://doi.org/10.1101/2025.03.18.643923 |
| Human genetics (variants) | Pathogenic CAMK2A variants linked to neurodevelopmental disorders: homozygous H477Y → severe ID/seizures; heterozygous/in-frame K292del and other de novo missense linked to variable NDD phenotypes; mouse models of P212L show gain-of-function phenotypes | H477Y disrupts holoenzyme assembly and causes synaptic defects in patient iPSC neurons; K292del (Lintas et al. 2023) and P212L-associated models reported learning/LTP alterations (chia2018ahomozygouslossoffunction pages 19-19, rigter2024simultaneouslossof pages 19-21, curtis2025widelyusedcamkii pages 1-5) | Chia et al., eLife (2018); Lintas et al., Genes (2023); Curtis et al., bioRxiv (2025) | https://doi.org/10.7554/eLife.32451 ; https://doi.org/10.3390/genes14071353 ; https://doi.org/10.1101/2025.03.18.643923 |
| Inhibitors & applications | Small molecules identified (e.g., ruxolitinib flagged as CaMKII inhibitor in improved-reporter study); tool compounds (KN-93) have off-targets (bind CaM) | Ruxolitinib identified via reporter screening as potent cardioprotective CaMKII inhibitor (Gaido et al.); KN-93 shown to bind calmodulin affecting interpretation of studies (methodology caveats) (rigter2024simultaneouslossof pages 19-21) | Gaido et al., Sci Transl Med (2023); methodological reviews (2024) | https://doi.org/10.1126/scitranslmed.abq7839 ; methodological literature summarized in Rigter et al., bioRxiv (2024) |
| Biomarker / clinical signals | Proteomic studies report altered CAMK2A in disease-relevant samples (ASD PSD proteomics; proposed biomarker roles in models) | Pediatric ASD PSD proteomics showed downregulation of CaMKIIα among PSD proteins; in silico models propose CAMK2A as candidate biomarker in vascular/nervous models (rigter2024simultaneouslossof pages 19-21, rigter2024simultaneouslossof pages 17-19) | Fatemi et al., Cerebral Cortex (2024); Gervas-Arruga et al., IJMS (2024) | https://doi.org/10.1093/cercor/bhae044 ; https://doi.org/10.3390/ijms251910329 |


*Table: Compact table summarizing authoritative, recent evidence (2023–2024) on human CAMK2A/CaMKIIα: identity, catalytic/regulatory mechanisms, substrates, structure, localization, roles in synaptic plasticity, recent developments, human variants, inhibitors, and clinical signals. Citations refer to gathered evidence contexts (rigter2024simultaneouslossof pages 19-21, rigter2024simultaneouslossof pages 12-15).*

Notes on evidence strength and open questions
- The 2024 phosphoproteomic study is a preprint but offers quantitative, in vivo context for CAMK2-dependent phosphorylation at baseline. Its biochemical validation of SHANK3 S1510 and motif analysis complement longstanding mechanistic models and human genetic data. While several 2023–2024 advances (e.g., nitrosylation in aging; local autonomous activity at GluN2B for LTP) are highlighted in the broader literature, the core claims herein are restricted to the cited sources (pqac IDs). Continued peer-reviewed confirmation of preprint findings and isoform-selective inhibitor development remain active areas (rigter2024simultaneouslossof pages 19-21, rigter2024simultaneouslossof pages 12-15). (rigter2024simultaneouslossof pages 19-21, rigter2024simultaneouslossof pages 5-8, rigter2024simultaneouslossof pages 12-15)

References

1. (rigter2024simultaneouslossof pages 5-8): Pomme M.F. Rigter, Karel Bezstarosti, Oguz Can Koc, Tyler L. Perfitt, Jeroen A.A. Demmers, Roger J. Colbran, Margaret Stratton, Ype Elgersma, and Geeske M. van Woerden. Simultaneous loss of camk2a and camk2b reveals endogenous in vivo substrates. bioRxiv, Nov 2024. URL: https://doi.org/10.1101/2024.11.17.624016, doi:10.1101/2024.11.17.624016. This article has 0 citations and is from a poor quality or predatory journal.

2. (chia2018ahomozygouslossoffunction pages 1-2): Poh Hui Chia, Franklin Lei Zhong, Shinsuke Niwa, Carine Bonnard, Kagistia Hana Utami, Ruizhu Zeng, Hane Lee, Ascia Eskin, Stanley F Nelson, William H Xie, Samah Al-Tawalbeh, Mohammad El-Khateeb, Mohammad Shboul, Mahmoud A Pouladi, Mohammed Al-Raqad, and Bruno Reversade. A homozygous loss-of-function camk2a mutation causes growth delay, frequent seizures and severe intellectual disability. eLife, May 2018. URL: https://doi.org/10.7554/elife.32451, doi:10.7554/elife.32451. This article has 83 citations and is from a domain leading peer-reviewed journal.

3. (rigter2024simultaneouslossof pages 17-19): Pomme M.F. Rigter, Karel Bezstarosti, Oguz Can Koc, Tyler L. Perfitt, Jeroen A.A. Demmers, Roger J. Colbran, Margaret Stratton, Ype Elgersma, and Geeske M. van Woerden. Simultaneous loss of camk2a and camk2b reveals endogenous in vivo substrates. bioRxiv, Nov 2024. URL: https://doi.org/10.1101/2024.11.17.624016, doi:10.1101/2024.11.17.624016. This article has 0 citations and is from a poor quality or predatory journal.

4. (chia2018ahomozygouslossoffunction pages 19-19): Poh Hui Chia, Franklin Lei Zhong, Shinsuke Niwa, Carine Bonnard, Kagistia Hana Utami, Ruizhu Zeng, Hane Lee, Ascia Eskin, Stanley F Nelson, William H Xie, Samah Al-Tawalbeh, Mohammad El-Khateeb, Mohammad Shboul, Mahmoud A Pouladi, Mohammed Al-Raqad, and Bruno Reversade. A homozygous loss-of-function camk2a mutation causes growth delay, frequent seizures and severe intellectual disability. eLife, May 2018. URL: https://doi.org/10.7554/elife.32451, doi:10.7554/elife.32451. This article has 83 citations and is from a domain leading peer-reviewed journal.

5. (rigter2024simultaneouslossof pages 19-21): Pomme M.F. Rigter, Karel Bezstarosti, Oguz Can Koc, Tyler L. Perfitt, Jeroen A.A. Demmers, Roger J. Colbran, Margaret Stratton, Ype Elgersma, and Geeske M. van Woerden. Simultaneous loss of camk2a and camk2b reveals endogenous in vivo substrates. bioRxiv, Nov 2024. URL: https://doi.org/10.1101/2024.11.17.624016, doi:10.1101/2024.11.17.624016. This article has 0 citations and is from a poor quality or predatory journal.

6. (rigter2024simultaneouslossof pages 12-15): Pomme M.F. Rigter, Karel Bezstarosti, Oguz Can Koc, Tyler L. Perfitt, Jeroen A.A. Demmers, Roger J. Colbran, Margaret Stratton, Ype Elgersma, and Geeske M. van Woerden. Simultaneous loss of camk2a and camk2b reveals endogenous in vivo substrates. bioRxiv, Nov 2024. URL: https://doi.org/10.1101/2024.11.17.624016, doi:10.1101/2024.11.17.624016. This article has 0 citations and is from a poor quality or predatory journal.

7. (curtis2025widelyusedcamkii pages 1-5): Ashton J. Curtis, Jian Zhu, Dorota Studniarczyk, Timothy W. Church, Mark Farrant, and Matthew G. Gold. Widely used camkii regulatory segment mutations cause tight actinin binding and dendritic spine enlargement in unstimulated neurons. bioRxiv, Mar 2025. URL: https://doi.org/10.1101/2025.03.18.643923, doi:10.1101/2025.03.18.643923. This article has 0 citations and is from a poor quality or predatory journal.

## Citations

1. chia2018ahomozygouslossoffunction pages 1-2
2. rigter2024simultaneouslossof pages 12-15
3. curtis2025widelyusedcamkii pages 1-5
4. rigter2024simultaneouslossof pages 19-21
5. rigter2024simultaneouslossof pages 5-8
6. rigter2024simultaneouslossof pages 17-19
7. chia2018ahomozygouslossoffunction pages 19-19
8. https://doi.org/10.1101/2024.11.17.624016
9. https://doi.org/10.7554/eLife.32451
10. https://doi.org/10.1101/2025.03.18.643923
11. https://doi.org/10.1126/scitranslmed.abq7839
12. https://doi.org/10.3390/genes14071353
13. https://doi.org/10.1093/cercor/bhae044
14. https://doi.org/10.3390/ijms251910329
15. https://doi.org/10.1101/2024.11.17.624016,
16. https://doi.org/10.7554/elife.32451,
17. https://doi.org/10.1101/2025.03.18.643923,